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Résumé en
anglais
Donor cell leukemia (DCL) is an infrequent complication after allogeneic
hematopoietic stem cell transplantation (HSCT). Its true incidence is difficult to
assess, although improvements in chimerism studies contributed to a better
diagnosis of DCL. We report two rare cases of donor cell-derived acute
promyelocytic leukemia (APL). To our knowledge, only two cases have been
described in the literature. Here, we report one male and one female patients with
acute myeloid leukemia (AML), who developed an APL in donor cells after HSCT.
The latency between HSCT and DCL was 279 and 43 months, respectively.
Fluorescent in situ hybridation and chimerism monitoring analysis proved the donor
origin of APL. Surprisingly, donor lymphocyte infusion provided a hematological
response during 19 months in the female patient. The mechanisms associated with
pathogenesis of DCL are unclear and seem to be multifactorial. Increasing
worldwide allogeneic hematopoietic stem cell transplantation activity and potentially
the age of donor could explain the increasing incidence of DCL in the future. It is
highlighted that long-term follow up of recipients will allow to report all cases of
DCL, to clarify the genetic landscape and factors which contribute to DCL, to
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